BioSpace News Archive

Heska Corporation, a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2022 Annual Meeting of Stockholders.

Valneva’s inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14th.

Longeveron Inc. announced today its Chief Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April.

Lexaria Bioscience Corp. announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.

The Carling Adrenal Center, a worldwide destination for the surgical treatment of adrenal tumors, becomes the first center to offer the use of amniotic membrane during adrenal surgery which saves functional adrenal tissue in patients undergoing adrenal surgery.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it will present at NobleCon18, Noble Capital Markets’ 18th Annual Investor Conference.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today that an independent retrospective study reported positive two-year clinical outcomes with the Vantage Ankle Fixed Bearing System.

Today, Health Canada authorized Evusheld (tixagevimab and cilgavimab) for the prevention of COVID-19.

Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions™ (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows.

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (≥12 years of age weighing at least 40kg).